2
Clinical Trials associated with Cell therapy(Assistance Publique–Hôpitaux de Paris (AP-HP))Treatment of the Bilateral Severe Uveitis by IVT of Regulator T-cells: Study of Tolerance of Dose
Uveitis is a leading cause of blindness in the children and young adult's populations. One third of etiology are idiopathic. The reference treatments are corticosteroids and immunosuppressive agents. They have significant side effects, and patient's compliance is often poor. In addition, some uveitis are more resistant. Also, in these situations of deadlock therapeutic, investigators propose a cell therapy by administering regulatory T cells (Tregs) in the vitreous of patients.
Injection of CD4 and CD8 + T Cells Anti-CMV or Anti-adenovirus for the Treatment of Viral Infections Occurring After Allogenic Hematopoietic Stem Cell Transplantation (HSCT)
The main purpose of this project is to evaluate the efficiency of the injection of CD4 and CD8+ T cell anti-Cytomegalovirus (CMV) on blood viral replication of CMV, 21 days after the first injection (adenovirus infection is not enough usual, especially in adults, to be used for the primary purpose and is measured in the secondary endpoints).
100 Clinical Results associated with Cell therapy(Assistance Publique–Hôpitaux de Paris (AP-HP))
100 Translational Medicine associated with Cell therapy(Assistance Publique–Hôpitaux de Paris (AP-HP))
100 Patents (Medical) associated with Cell therapy(Assistance Publique–Hôpitaux de Paris (AP-HP))
100 Deals associated with Cell therapy(Assistance Publique–Hôpitaux de Paris (AP-HP))